List view / Grid view
20 July 2015 | By
Amgen has announced the top-line results of a Phase 2 trial evaluating blinatumomab in adults with relapsed or refractory Ph+ B-cell precursor ALL...
20 July 2015 | By Victoria White
The US FDA has designated Motif Bio's iclaprim as a Qualified Infectious Diseases Product (QIDP) for hospital acquired bacterial pneumonia (HABP)...
17 July 2015 | By Victoria White
GSK has begun shipping Flaurix Quadrivalent (flu vaccine) doses to US healthcare providers and expects to begin shipping Flulaval Quadrivalent in August...
16 July 2015 | By Victoria White
The EC has approved Evotaz tablets in combination with other antiretroviral agents for the treatment of HIV-1 infected adults...
16 July 2015 | By Victoria White
CPhI Worldwide has announced the addition of four new high profile experts to the CPhI annual report, taking the total up to a record 14 panellists for 2015...
16 July 2015 | By
Boehringer Ingelheim has welcomed new international treatment guidelines for IPF which suggest that clinicians use Ofev in patients with the disease...
16 July 2015 | By Victoria White
Akorn Pharmaceuticals seeks approval to market a generic version of Allergan's Restasis from the US Food and Drug Administration FDA...
16 July 2015 | By Victoria White
Immunocore Limited has announced the completion of a £205 million private financing round, allowing it to further accelerate its pipeline of ImmTACs...
16 July 2015 | By Victoria White
Coartem 80/480mg has received WHO prequalification, making it the first high strength ACT antimalarial treatment available for public sector procurement...
16 July 2015 | By Victoria White
Data from a post-hoc subset analysis of Phase IIb clinical trials suggests the potential efficacy of Otsuka’s delamanid for the treatment of XDR-TB...
15 July 2015 | By Victoria White
Scientists have discovered a new subtype of emm89 streptococcus that has contributed to a rise in disease cases in the UK over the last 17 years...
15 July 2015 | By Victoria White
Oxford Vaccine Group has initiated a Phase 2 clinical study of the Ebola prime-boost vaccine regimen that combines MVA-BN-Filo with Ad26.ZEBOV...
15 July 2015 | By Victoria White
Sanofi plans to evolve its business with the creation of five Global Business Units: General Medicines & Emerging Markets, Specialty Care, Diabetes & Cardiovascular, Sanofi Pasteur and Merial.
15 July 2015 | By Victoria White
The anti-hypertensive therapeutics market in the Asia-Pacific will expand in value from $15.7b in 2014 to reach $19.9b by 2021, says GBI Research...
15 July 2015 | By Victoria White
Takeda has submitted an NDA to the US FDA for ixazomib for the treatment of patients with relapsed and/or refractory multiple myeloma...
